British researchers successfully delivered eight healthy children using mitochondrial replacement therapy, a specialized IVF technique that incorporates DNA from three individuals. The procedure combines nuclear DNA from both intended parents with healthy mitochondria from a donor egg, effectively preventing transmission of debilitating mitochondrial diseases that affect cellular energy production. This represents a landmark achievement in reproductive medicine, offering hope to women carrying mitochondrial mutations who previously faced near-certain disease transmission to offspring. The technique addresses a critical gap in fertility treatment since mitochondrial disorders can cause severe neurological, muscular, and metabolic complications. While the sample size remains small, these successful births validate years of laboratory research and represent the first clinical proof-of-concept for germline mitochondrial replacement in humans. The approach fundamentally differs from traditional gene therapy by replacing defective cellular powerhouses rather than correcting individual genetic defects. However, broader implementation will require extensive long-term monitoring of the children's health, resolution of complex ethical considerations around germline modification, and regulatory approval across different jurisdictions. The success rate and optimal patient selection criteria also need refinement through larger clinical cohorts.